Fig. 4: YME1L depletion inhibits proliferation, viability, cell cycle progression and migration of primary human NPC cells.

The stable pNPC-1 primary NPC cells with the lentiviral YME1L shRNA (“kdYME1L”), the lentiviral CRISPR-YME1L-KO construct (koYME1L), or the lentiviral scramble control shRNA plus the lentiviral CRISPR-KO control treatment (“ctrl”) were established, the exact same number of the above pNPC-1 cells were cultivated for designated hours, cell proliferation, viability, cell cycle progression, migration, invasion were tested via nuclear EdU fluorescence staining (A), CCK-8 (B), PI-FACS (C), “Transwell” (D) and “Matrigel Transwell” (E) assays, respectively. Primary NPC cells that were derived from other patients, pNPC-2/-3/-4, or the primary human nasal epithelial cells (pHNEpC-1 and pHNEpC-2, derived from two donors) were stably transduced with the lentiviral YME1L shRNA (“kdYME1L”) or the lentiviral scramble control shRNA (“kdC”); The exact same number of cells were further cultivated for designated hours, cell proliferation (F and J), migration (G) and viability (H and I) were tested similarly. The numerical values were mean ± standard deviation (SD, n = 5). “pare” indicates the parental control cells. *P < 0.05 vs. “pare”/“kdC” cells. “N. S.” stands for non-statistical difference (P > 0.05). Experiments in this figure were repeated five times, and each time similar results obtained. Scale bar = 100 μm.